9 completed, 2 recruiting. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Recruiting 1 |
| Phase 1 | 4 | Completed 4 |
Follow Cervical Small Cell Carcinoma: new trials by email Literature Review of Cervical Small Cell Carcinoma trials Research Report on Cervical Small Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda Hypofractionated Radiation Therapy, Conventional Fractionated Radiotherapy, Cisplatin - Cervical Cancer, Cervix Cancer | Phase 2 | Recruiting | Uganda Cancer Institute | 278 | 2026-03-11 | 2026-03-27 |
| Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Axalimogene filolisbac - Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer | Phase 1 | Completed | Advaxis, Inc. | 12 | 2015-03-04 | 2024-05-20 |
| Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix Follow-Up, Medical Chart Review - Cervical Large Cell Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma | Recruiting | M.D. Anderson Cancer Center | 750 | 2013-05-16 | 2026-09-14 | |
| Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2011-02-01 | 2019-08-08 |
| Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer fludeoxyglucose F 18, positron emission tomography, computed tomography - Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 384 | 2007-09-01 | 2019-07-23 |
| Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes Laboratory Biomarker Analysis, Lymphadenectomy - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Completed | Gynecologic Oncology Group | 159 | 2007-04-02 | 2017-08-24 | |
| ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 37 | 2006-11-01 | 2019-01-08 |
| Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Conventional Surgery - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 38 | 2006-01-01 | 2015-05-29 |
| Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Internal Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Cetuximab - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 64 | 2005-01-01 | 2014-12-31 |
| Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer Gemcitabine Hydrochloride, Cisplatin, Radiation Therapy - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 13 | 2003-10-01 | 2014-12-25 |
| Collecting Tumor Samples From Patients With Gynecological Tumors Laboratory Biomarker Analysis - Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor | Completed | Gynecologic Oncology Group | 275 | 1992-06-01 | 2016-10-28 |
Uterine Cervical Neoplasms (11) · Adenocarcinoma (1) · Brenner Tumor (1) · Carcinoma (1) · Carcinoma, Adenosquamous (1) · Carcinoma, Small Cell (1) · Carcinoma, Squamous Cell (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gestational Trophoblastic Disease (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Neoplasms (1)
Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Genital Diseases (11) · Urogenital Diseases (11) · Genital Diseases, Female (10) · Genital Neoplasms, Female (10) · Neoplasms (10) · Neoplasms by Site (10) · Urogenital Neoplasms (10) · Uterine Cervical Diseases (10) · Uterine Diseases (10) · Uterine Neoplasms (10) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms, Complex and Mixed (2)
Brachytherapy (3) · Cisplatin (3) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Albumin-Bound Paclitaxel (1) · Blood Specimen Collection (1) · Cetuximab (1) · Chromatin Immunoprecipitation Sequencing (1) · Filgrastim (1) · Fluorodeoxyglucose F18 (1) · Follow-Up Studies (1) · Gemcitabine (1) · Granulocyte Colony-Stimulating Factor (1) · Lymph Node Excision (1) · Magnetic Resonance Spectroscopy (1) · Platinum (1)
Gynecologic Oncology Group (6) · National Cancer Institute (NCI) (2) · Advaxis, Inc. (1) · M.D. Anderson Cancer Center (1) · Uganda Cancer Institute (1)
United States (10) · Canada (1) · Japan (1) · South Korea (1) · Spain (1) · Uganda (1)
Charles Kunos (1) · D. McMeekin (1) · David Alberts (1) · Kathleen Moore (1) · Larissa A. Meyer (1) · Michael Cibull (1) · Michael Gold (1) · Mostafa Atri (1) · Peter Rose (1) · Solomon Kibudde, MBChB, MMed. (1)
U10CA027469 (7), U10CA180868 (4), D43TW009759 (1)